## Hemraj Dodiya

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2829674/publications.pdf

Version: 2024-02-01

25 papers 4,300 citations

331670
21
h-index

24 g-index

25 all docs

25 docs citations

25 times ranked

5659 citing authors

#	Article	IF	CITATIONS
1	Gut microbiota–driven brain Aβ amyloidosis in mice requires microglia. Journal of Experimental Medicine, 2022, 219, .	8.5	44
2	Microbiome Medicine: Microbiota in Development and Management of Cardiovascular Diseases. Endocrine, Metabolic and Immune Disorders - Drug Targets, 2022, 22, 1344-1356.	1.2	2
3	Chronic stress-induced gut dysfunction exacerbates Parkinson's disease phenotype and pathology in a rotenone-induced mouse model of Parkinson's disease. Neurobiology of Disease, 2020, 135, 104352.	4.4	172
4	Future of Probiotics and Prebiotics and the Implications for Early Career Researchers. Frontiers in Microbiology, 2020, $11,1400$ .	3.5	30
5	Sex-specific effects of microbiome perturbations on cerebral $\hat{Al^2}$ amyloidosis and microglia phenotypes. Journal of Experimental Medicine, 2019, 216, 1542-1560.	8.5	165
6	Role of TLR4 in the gut-brain axis in Parkinson's disease: a translational study from men to mice. Gut, 2019, 68, 829-843.	12.1	290
7	Gut–brain and brain–gut axis in Parkinson's disease models: Effects of a uridine and fish oil diet. Nutritional Neuroscience, 2018, 21, 391-402.	3.1	68
8	Gut bacterial composition in a mouse model of Parkinson's disease. Beneficial Microbes, 2018, 9, 799-814.	2.4	72
9	Colon dysregulation in methamphetamine self-administering HIV-1 transgenic rats. PLoS ONE, 2018, 13, e0190078.	2.5	25
10	The Potential Role of Gut-Derived Inflammation in Multiple System Atrophy. Journal of Parkinson's Disease, 2017, 7, 331-346.	2.8	68
11	The gut-brain axis in Parkinson's disease: Possibilities for food-based therapies. European Journal of Pharmacology, 2017, 817, 86-95.	3.5	155
12	Alcohol Feeding in Mice Promotes Colonic Hyperpermeability and Changes in Colonic Organoid Stem Cell Fate. Alcoholism: Clinical and Experimental Research, 2017, 41, 2100-2113.	2.4	37
13	NPT088 reduces both amyloidâ $\hat{\epsilon}^2$ and tau pathologies in transgenic mice. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 141-155.	3.7	36
14	Human Neural Stem Cells Survive Long Term in the Midbrain of Dopamine-Depleted Monkeys After GDNF Overexpression and Project Neurites Toward an Appropriate Target. Stem Cells Translational Medicine, 2014, 3, 692-701.	3.3	36
15	Neonatal immune-tolerance in mice does not prevent xenograft rejection. Experimental Neurology, 2014, 254, 90-98.	4.1	24
16	P4-213: REDUCTION OF $\hat{l}^2$ -AMYLOID AND PHOSPHO-TAU IN TRANSGENIC MICE BY A NOVEL FUSION PROTEIN BIVALENT FOR A GENERAL AMYLOID INTERACTION MOTIF (GAIM)., 2014, 10, P866-P866.		0
17	Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. Brain, 2013, 136, 2419-2431.	7.6	965
18	Enduring cortical alterations after a single in-vivo treatment of HIV-1 Tat. NeuroReport, 2012, 23, 825-829.	1.2	24

#	Article	IF	CITATIONS
19	Is alphaâ€synuclein in the colon a biomarker for premotor Parkinson's Disease? Evidence from 3 cases. Movement Disorders, 2012, 27, 716-719.	3.9	383
20	Alphaâ€synuclein in colonic submucosa in early untreated Parkinson's disease. Movement Disorders, 2012, 27, 709-715.	3.9	381
21	Transfer of host-derived alpha synuclein to grafted dopaminergic neurons in rat. Neurobiology of Disease, 2011, 43, 552-557.	4.4	149
22	Cell Transplantation and Gene Therapy in Parkinson's Disease. Mount Sinai Journal of Medicine, 2011, 78, 126-158.	1.9	43
23	Increased Intestinal Permeability Correlates with Sigmoid Mucosa alpha-Synuclein Staining and Endotoxin Exposure Markers in Early Parkinson's Disease. PLoS ONE, 2011, 6, e28032.	2.5	689
24	Differential Transduction Following Basal Ganglia Administration of Distinct Pseudotyped AAV Capsid Serotypes in Nonhuman Primates. Molecular Therapy, 2010, 18, 579-587.	8.2	82
25	Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiology of Disease, 2009, 35, 385-398.	4.4	360